Document:

Distribution Areement

 Exhibit 10.33 
 Confidential information redacted and filed separately with the Commission. 

Omitted portions indicated by [***] 
 ClearVue Supplier Agreement 
 This Agreement, dated as
of January 1, 2012 (the “Effective Date”), is by and between United Natural Foods, Inc., a Delaware corporation, having an office at 313 Iron Horse Way, Providence, RI 02908 (collectively, with its subsidiaries and affiliates,
“UNFI”) and Annie’s, Inc., a Delaware corporation, having an office at 1610 5th Street, Berkeley, CA 94710 (collectively, with its subsidiaries and affiliates, the “Supplier” or “Annie’s”). 

WITNESSETH 

WHEREAS, UNFI is the leading distributor of natural foods products in the United States; and 

WHEREAS, UNFI distributes Supplier’s products under the brand names “Annie’s Homegrown”, “Annie’s
Naturals”; and “Consorzio by Annie’s Naturals”. 
 WHEREAS, UNFI is willing to include Supplier in
UNFl’s proprietary ClearVue program, under which each party will have certain rights and obligations as set forth in Exhibits A and B hereto and incorporated by reference herein. 

NOW, THEREFORE, the parties hereto, for the mutual premises set forth herein and other good and valuable consideration, the receipt and
sufficiency of which is hereby acknowledged, and intending to be legally bound, hereby agree as follows: 
 1. UNFI’s Obligations.
UNFI will provide certain sales, marketing, information and administrative services as fully set out in Exhibit A, attached hereto and incorporated herein. 
 2. Supplier’s Obligations. In consideration of the services provided by UNFI hereunder, Supplier agrees to all terms and conditions herein and in Exhibit B, including its agreement to:

 A. Participate in UNFI sales and marketing programs, as they may be offered from time to time, at a level reasonably related
to sales volume, as determined by UNFI in its reasonable discretion. 
 B. Maintain an [***] at or above the level in place as
of the signing of this Agreement. 
 C. Assign a senior account executive reasonably acceptable to UNFI to manage national
activity throughout the country. 
 D. Accept returns of products for unsuccessful new product introductions, where/ when
applicable, after a minimum eight-month introductory period, as long as returned products reach Supplier within shelf life, in resalable condition and packed in original containers. 

E. It is the goal of the parties to limit out-of-stocks by Supplier to no more than [***]%; overall, and no greater than [***]% on items
designated by UNFI as strategic, exclusive of material unexpected swings in UNFI ordering patterns, or a Force Majeure event as defined below in Section 5.E. 
 F. Assist UNFI in determining the ideal product mix and inventory level for Supplier’s products. 

  

					
	Confidential Information Redacted	 	1	 	Confidential Treatment Requested

 G. Grant UNFI discounts/rebates [***] 
 3. Interference with UNFI Contractual Relations The parties intend, through execution of this Agreement, to increase mutually profitable sales through UNFI. The parties acknowledge that part of
Supplier’s business strategy is to increase the placement of its products in the mainline aisles [***]. Supplier agrees that (1) [***], and (2) during the term [***] 
 4. Confidential Information. 
 A. UNFI considers its ClearVue program
(including both the technical and the financial aspects) to be highly confidential proprietary information owned by UNFI, and Supplier may not disclose any information related to the program to any third party, as more fully set forth below.

 B. Company and Supplier each acknowledge that by reason of the relationship established under this Agreement, each party
(“Receiving Party”) may be granted access to information relating to the other party’s (“Disclosing Party”) operations, technology, know-how, and any other information deemed confidential by such Disclosing Party.

 (1) Definition of Confidential Information. For the purposes of this Agreement, “Confidential
Information” means, with respect to the applicable Disclosing Party: (a) any information relating to processes, formulae, procedures, materials, marketing, products and their design and manufacture, methods of operation, sales and profit data,
business plans, business opportunities, finances, cash flow, accounts receivables, research, development, know-how, personnel, customer and supplier lists, and relationships between Company or Supplier and its respective customers, suppliers and
others who have business dealings with it, other information not readily available to the public, and plans for future developments relating thereto; (b) any information that is treated as confidential by Disclosing Party and would reasonably be
understood to be confidential, whether or not so marked; and (c) the terms and conditions of this Agreement; provided, however, that “Confidential Information” will not include information that: (w) is now or
subsequently becomes generally available to the public through no fault or breach on the part of the Receiving Party; (x) the Receiving Party can demonstrate by clear and convincing evidence to have had rightfully in its possession prior to
disclosure; (y) is independently developed by personnel of the Receiving Party who had no substantive knowledge of Confidential Information at the time of such independent development; or (z) is rightfully obtained from a third party who has the
right to transfer or disclose it. 
 (2) Nondisclosure and Nonuse of Confidential Information. Receiving Party
will not use Confidential Information for any purpose other than to fulfill its obligations under this Agreement. Receiving Party will not disclose, publish, or disseminate Confidential Information to anyone other than (a) those of its
employees and agents who have been informed of the confidential nature of the 

  

					
	Confidential Information Redacted	 	2	 	Confidential Treatment Requested

 Confidential Information and have a “need to know” such Confidential Information in order to
perform and provide the obligations contemplated under this Agreement or (b) as required by a subpoena, judicial, or administrative process. Receiving Party agrees to protect Confidential Information against any unauthorized use, disclosure,
publication, or dissemination with the same degree of care that Receiving Party uses to protect and safeguard its own confidential information, but not less than the degree of care that would be exercised by a prudent person given the sensitivity
and strategic value of such Confidential Information. Receiving Party agrees to accept and use Confidential Information for the sole purpose of transacting its business with Disclosing Party. Receiving Party agrees not to use Confidential
Information otherwise for its own or any third party’s benefit without the prior written approval of an authorized representative of Disclosing Party in each instance. 
 (3) Ownership of Confidential Information. All Confidential Information, including Derivatives thereof, remains the property of the Disclosing Party and, except as expressly provided herein,
no license or other rights to Confidential Information is hereby granted or implied. For purposes of this Agreement, “Derivatives” means (a) for copyrightable or copyrighted material, any translation, abridgment, revision or other form in
which an existing work may be recast, transformed or adapted; (b) for patentable or patented material, any improvement thereon; and (c) for material that is protected by trade secret, any new material derived from such existing trade secret
material, including new material that may be protected by copyright, patent and/or trade secret. At Disclosing Party’s expense, Receiving Party will take such action and execute such documents as Disclosing Party may reasonably request to
warrant and confirm Disclosing Party’s title to and ownership of all such Derivatives and their proceeds and to transfer and assign to Disclosing Party any rights that Receiving Party may have therein. 

(4) Return of Documents. Within [***] business days of receipt of Disclosing Party’s written request, Receiving Party
will return to Disclosing Party all documents, records and copies thereof containing Confidential Information. For purposes of this section, the term “Documents” includes all information fixed in any tangible medium of expression, in
whatever form or format. 
 (5) Equitable Relief. Company and Supplier hereby acknowledge that unauthorized
disclosure or use of Confidential Information could cause irreparable harm and significant injury to Disclosing Party that may be difficult to ascertain. Accordingly, Receiving Party agrees that Disclosing Party will have the right to seek and
obtain immediate injunctive relief to enforce obligations under this Agreement in addition to any other rights and remedies it may have. The rights and remedies of Disclosing Party are cumulative and the exercise or enforcement of any one or more of
them will not preclude Disclosing Party from exercising or enforcing any other right or remedy. The delay or failure by Disclosing Party to exercise any of its rights in any one instance will not preclude Disclosing Party from exercising its rights
at a later time in that instance or at any other time in any other instance. 
 5. Term and Termination. 

A. Subject to the provisions of Section 5.B, the initial term of this Agreement will commence on January 9, 2012 and end on the two year
anniversary date. The term of this Agreement will automatically be extended for successive one (2) year period unless UNFI or the Supplier elects not to extend such term by written notice to the other at least sixty (60) days prior to the end
of the then current term. 
 B. This Agreement may be terminated by either party upon the occurrence of any one or more of the
following events of default: (a) failure by a party to pay or perform any obligation under this Agreement and the continuation of such failure for [***] days after receipt of notice thereof; (b) 

 

  

					
	Confidential Information Redacted	 	3	 	Confidential Treatment Requested

 the entering into or filing by or against a party of a petition, arrangement or proceeding seeking an order
for relief under the bankruptcy laws of the United States, of any of the states of the United States or any other country, a receivership for any of the assets of a party, a composition with or assignment for the benefit of its creditors, a
readjustment of debt, or the dissolution or liquidation of a party; or (c) the insolvency of a party. Upon termination, the terminating party will have all rights available to it at law and equity. 

6. General Provisions. 

A. This Agreement, including the Exhibits attached hereto, constitutes the entire Agreement of the parties hereto with respect to the
subject matter hereof, and supersedes all prior oral or written agreements and all other negotiations, agreements, covenants and representations. This Agreement may not be amended or modified, except by a further written agreement signed by the
parties hereto. Notwithstanding the foregoing, if the parties hereto are parties to an agreement for the sale of products by Supplier to UNFI (a “Supply Agreement”), this Agreement will not supersede such agreement and in the event of a
conflict in terms between this Agreement and the Supply Agreement, the terms of the Supply Agreement will prevail. 
 B. No
failure or delay on the part of any party in exercising any right or remedy hereunder will operate as a waiver thereof; nor will any single or partial exercise of any such right or remedy preclude any other or further exercise thereof or of any
other right or remedy. No provision of this Agreement may be waived except in a writing signed by the party granting such waiver. Neither party may assign its rights hereunder to any third party without the prior written consent of the other party,
except that either party may assign its rights under this Agreement without the consent of the other party in the event of a sale of substantially all the assigning party’s assets. In the event that any one or more of the provisions, or parts
of any provisions, contained in this Agreement are for any reason held to be invalid, illegal, or unenforceable in any respect by a court of competent jurisdiction, the same will not invalidate or otherwise affect any other provision hereof, and
this Agreement will be construed as if such invalid, illegal or unenforceable provision had never been contained herein. 
 C.
All notices, requests, demands, payments, consents and other communications hereunder will be transmitted in writing and will be deemed to have been duly given when hand delivered, upon delivery when sent by express mail, courier, overnight mail or
other overnight or next-day delivery service, or on the date mailed when sent by registered or certified United States mail, postage prepaid, return receipt requested, to the addresses set forth above. Each party may change its address by giving
notice of such change of address to the other party in the manner described above. 
 D. This Agreement will be governed by the
laws of the State of Rhode Island, without regard to its rules regarding conflict of laws. The parties agree that service of process by certified mail, return receipt requested, will be deemed adequate service of process. In the event of a breach of
the terms of this Agreement, the breaching party hereby agrees to reimburse the non-breaching party for all costs and expenses, including reasonable attorney’s fees, incurred by it in enforcing the obligations hereunder. 

E. Force Maleure. Neither party will be liable to the other party for any loss, delay or failure to perform resulting directly or
indirectly from fires, floods, riots, strikes or other circumstances beyond either party’s reasonable control. In the event of a force majeure occurrence, the disabled party will make all reasonable efforts to remove such disability within 30
days of giving notice of such disability. During such period, the non-disabled party may seek to have its needs, which would 

  

					
	Confidential Information Redacted	 	4	 	Confidential Treatment Requested

 
otherwise be met hereunder, met by others without liability to the disabled party hereunder. If the disability continues for more than 10 days after the cessation of the reason for such
disability, the non-disabled party will have the right to terminate this Agreement immediately. 
 F. Guaranty/Warranty of
Product. Supplier guarantees and warrants that: 
 (1) All intellectual property or proprietary rights used by Supplier in
connection with its products are owned by Supplier or Supplier has been properly authorized to use such rights in connection with the products and to sell the products that incorporate such proprietary rights to UNFI for use or further resale;

 (2) All products are manufactured, packaged, labeled, packed, shipped and invoiced in compliance with the applicable
requirements of federal, state and local laws, regulations, ordinahces and administrative orders and rules of the United States and all other countries in which the product is manufactured or delivered and that all such required labeling is affixed
to products as required and passed on to UNFI or its customers; 
 (3) If applicable, all advertising and promotional materials
developed or provided by Supplier for any product will comply with all applicable requirements of federal, state and local laws, regulations, ordinances and administrative orders and rules of the United States and all other countries in which the
product is delivered, including, without limitation and if applicable, those promulgated by the U.S. Food and Drug Administration, the U.S. Department of Agriculture, the U.S. Federal Trade Commission and the Environmental Protection Agency;

 (4) Supplier and all employees and agents involved in the manufacturing, processing or delivery of the products will strictly
adhere to all applicable federal, state and local laws, regulations and prohibitions of the United States, its territories and all countries in which the product is produced or delivered with respect to the operation of their production facilities
and their other business and labor practices. 
 (5) Supplier certifies that neither Supplier nor its principals (owners/senior
officials) are debarred or suspended from U.S. Government procurement programs under the rules prescribed at Title 48 of the Code of Federal Regulations, Subpart 9.4 (48 C.F.R. §§ 9.400-9.409), and Supplier will promptly (within 15 days)
notify UNFI of any change in this status, including Supplier’s receipt of any notice proposing Supplier for debarment or suspension from U.S. Government procurement programs. 

(6) Supplier has obtained any and all licenses, permits, and authority necessary or required to perform its obligations under this
Agreement and has paid all fees and charges with reference thereto; that it is in good standing with all governmental bodies or agencies; that it will take such steps and perform such acts as may be necessary to retain such good standing; that it is
free and has full right and authority to enter into this Agreement and to perform all of its obligations hereunder; and that it has performed all acts and taken all steps necessary to authorize the execution of this Agreement. 

Supplier acknowledges that UNFI has no independent obligation to provide customers with Supplier’s warranty information beyond that
labeled on the product. 
 G. Indemnification. Supplier will indemnify, defend, and hold UNFl, its affiliates and
subsidiaries and their officers, directors; employees and agents, as well as any customers of UNFI and its subsidiaries harmless from and against any allegations asserted or damages, liabilities, losses, costs or

  

					
	Confidential Information Redacted	 	5	 	Confidential Treatment Requested

 
expenses (including reasonable attorneys’ fees) sought in any claim, action, lawsuit or proceeding connected with or arising out of any of the following (collectively, “Claims”):

 (1) Infringement or misappropriation of any patent, trademark, trade name, trade dress, copyright, trade secret or other
proprietary right in connection with the Supplier’s products; 
 (2) Death of or injury to any person, damage to any
property, or any other damage or loss resulting or claimed to have resulted, in whole or in part, from any quality or other defect in the products, whether latent or patent, or failure of Supplier’s products to comply with any express
or implied warranties or any claim of strict liability in tort relating to the products; 
 (3) Violation of any federal,
state or local laws, regulations, ordinances or administrative orders or rules of the United States, its territories or any other country in which Supplier’s products are produced or delivered relating to (A) the product, or any label,
packaging or invoice associated with the product, in its manufacture, possession, storage, use or sale; or (B) any advertising or promotional materials developed or provided by Supplier; 

(4) Defect involving the packaging, labeling, packing, shipping and/or invoicing of products; or 

(5) Failure to comply with any provisions of this Agreement. 
 Notwithstanding the foregoing, Supplier will not be liable to UNFI, and UNFI will indemnify Supplier, to the extent UNFI’s damages are determined to result from UNFI’s gross negligence or
willful misconduct. 

  

					
	Confidential Information Redacted	 	6	 	Confidential Treatment Requested

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement by and through their
duly authorized officers, as of the Effective Date. 
  

											
	United Natural Foods, Inc.	 		 		 	Annie’s, Inc.
						
	By:	 	 /s/ John Raiche
	 		 		 	By:	 	 /s/ John Foraker

		 	Signature	 		 		 		 	signature
						
	Name (printed/typed):	 	 John Raiche
	 		 		 	Name (printed/typed):	 	 John Foraker

						
	Title:	 	 VP Marketing
	 		 		 	Title:	 	 CEO

						
	Date signed:	 	 2/20/12
	 		 		 	Date signed:	 	 2/17/12

  

					
	Confidential Information Redacted	 	7	 	Confidential Treatment Requested

 Exhibit A 
 UNFI Obligations 
 UNFI will use its best efforts to fulfill the following obligations. The
use of terms such as “exclusive,” “preferred” or “priority” does not mean that UNFI is excluding suppliers of similar products from the ClearVue program. These terms are designed to differentiate between those suppliers
who do and do not participate in the ClearVue Program. The list of benefits referenced below is not intended to remain static; UNFI reserves the right to add, delete or modify benefits in its reasonable discretion in response to industry trends,
market conditions or other factors deemed important by UNFI in its reasonable discretion. 
 Sales and Marketing 

 

	 	•	 	 [***] 

  

	 	•	 	 Efficient approval, pick-up, product number assignment, and initial order placement of new products that are anticipated to be accretive to category
sales. 

  

	 	•	 	 [***]                     maximizing the mutual
benefit of this program. 

  

	 	•	 	 Strong partnership with UNFI Purchasing, Sales and Marketing. 

 

	 	•	 	 [***] 

	 	•	 	 [***] 

	 	•	 	 [***] 

	 	•	 	 [***] 

  

	 	•	 	 [***]                     UNFI’s Category
Management and Plan-o-gram service, [***] in brand and product selection/rationalization, merchandising location, and point of sale aids as applicable/appropriate. 

 

	 	•	 	 Joint efforts to reduce of out of stock situations [***] 

 

	 	•	 	 Reduced inventory needs at supplier facilities through better visibility [***] 

 

	 	•	 	 Complete alignment of objectives with UNFI, [***] 

  

	 	•	 	 Single Terms and Conditions nationally with UNFI. 

  

	 	•	 	 Joint efforts to identify and realize efficiencies [***] 

 

	 	•	 	 Preferred locations [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] marketing programs including [***] 

  

	 	•	 	 Three free inclusions [***]                    
program per year 

  

	 	•	 	 Two Shipper Program opportunities per year 

  

	 	•	 	 Two insertions for Monthly [***] 

  

	 	•	 	 Supermarket program opportunities, including [***] 

  

	 	•	 	 New item push programs 

  

	 	•	 	 Opportunity for a special [***]                    
at no additional charge 

  

	 	•	 	 Significant focus on [***] 

  

	 	•	 	 Web site links from the UNFI web site to ClearVue Supplier web sites. 

  

					
	Confidential Information Redacted	 	8	 	Confidential Treatment Requested

 Confidential Information 

 

	 	•	 	 Full visibility into the efficacy of [***] 

	 	•	 	 [***] 

  

	 	•	 	 [***] 

	 	•	 	 [***] 

  

	 	•	 	 Identify [***] 

	 	•	 	 Investment/return analysis [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 Quarterly excel based
[***]                            reports 

 

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 Fiscal Year End Report-excel based
[***]                            reports 

 

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 Access to detailed [***] 

  

	 	•	 	 Access to detailed [***] 

  

	 	•	 	 Access to detailed [***] 

  

	 	•	 	 Access to detailed [***] 

  

	 	•	 	 Access to detailed [***] 

  

	 	•	 	 Complete visibility of efficacy [***] 

  

	 	•	 	 Access to [***]
                                        at no
additional charge. 

  

	 	•	 	 Quarterly supplier product sales by [***] 

  

	 	•	 	 Quarterly listing of large grocery and supernatural chains carrying the brand [***] 

 

	 	•	 	 Quarterly supplier product sales nationally 

  

	 	•	 	 Quarterly supplier product sales by region 

  

	 	•	 	 Quarterly supplier product sales by state 

  

	 	•	 	 Quarterly points of distribution by state 

  

	 	•	 	 [***] 

  

					
	Confidential Information Redacted	 	9	 	Confidential Treatment Requested

 Exhibit B 
 Supplier Obligations 
 Annual [***] program to be executed based on mutual agreement to
track with Annie’s fiscal year timing (Mar-Apr) at objective to [***] 
 Annie’s will continue to support UNFI Marketing Programs
[***] 
 [***] 

Annie’s will participate in UNFl’s East and West Sales Meetings 
 Annie’s will provide a bi-monthly recap[***]                     in order to ensure visibility 

Annie’s will pay [***] 
 Payments due at the end of each quarter. 
 ClearVue benefits include: 

[***] 
 Annie’s will work with UNFI to
identify and implement logistics and supply chain opportunities to reduce costs for Annie’s and/or UNFI. [***] 
 Annie’s will provide
UNFI with an early pay discount of [***]                     on all purchases. 
 Discount applies to all Annie’s brands 
 Annie’s will provide UNFI a distributor
allowance equal to [***]                    , payable quarterly. 
 Annie’s will work with UNFI toward gaining placement of the [***]                     Annie’s
SKUs to close any distribution gaps of those particular products. 
 • [***] 

  

					
	Confidential Information Redacted	 	10	 	Confidential Treatment RequestedEX-4.7

 Exhibit 4.7 
 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT FOR AND PURSUANT TO THE
PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE
SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 

WARRANT TO PURCHASE STOCK 
  

			
	 Company:
	    	Somaxon Pharmaceuticals, Inc., a Delaware corporation
	 Number of Shares:
	    	50,000, as may be adjusted from time to time hereafter in accordance with the provisions of this Warrant
	 Class of Stock:
	    	Common Stock, $0.0001 par value per share
	 Warrant Price:
	    	$0.50 per share, as may be adjusted from time to time hereafter in accordance with the provisions of this Warrant
	 Issue Date:
	    	December 19, 2011
	 Expiration Date:
	    	December 19, 2021
	 Credit Facility:
	    	This Warrant is issued in connection with that certain Payoff Letter relating to the Loan and Security Agreement dated as of August 2, 2011 among Silicon Valley Bank, Oxford Finance LLC
and the Company (the “Loan Agreement”)

 THIS WARRANT CERTIFIES THAT, for good and valuable consideration, including without limitation the
mutual promises contained in the Loan Agreement, SILICON VALLEY BANK (together with any registered holder from time to time of this Warrant or any holder of the shares issuable or issued upon exercise of this Warrant, “Holder”) is entitled
to purchase the number of fully paid and non-assessable shares (the “Shares”) of the above-stated Class of Stock (the “Class”) of the above-named company (the “Company”) at the above-stated Warrant Price, all as set
forth above and as adjusted pursuant to Article 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. 
 ARTICLE 1. EXERCISE. 
 1.1 Method of Exercise. Holder may exercise this
Warrant by delivering the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached as Appendix 1 to the principal office of the Company. Unless Holder is exercising the conversion right set forth
in Article 1.2, Holder shall also deliver to the Company a certified or bank check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate Warrant Price for the
Shares being purchased. 
 1.2 Conversion Right. In lieu of exercising this Warrant as specified in Article 1.1,
Holder may from time to time convert this Warrant, in whole or in part, into a number of Shares determined by dividing (a) the aggregate fair market value of the Shares or other securities otherwise issuable upon exercise of this Warrant minus
the aggregate Warrant Price of such Shares by (b) the fair market value of one Share. The fair market value of the Shares shall be determined pursuant to Article 1.3. 

 1.3 Fair Market Value. If the Class is traded in a public market, the fair
market value of a Share shall be the average closing prices of a share of common stock reported for the three (3) business days immediately before Holder delivers this Warrant together with its Notice of Exercise to the Company. If the Class is
not traded in a public market, the Board of Directors of the Company shall determine fair market value in its reasonable good faith judgment. 
 1.4 Delivery of Certificate and New Warrant. Promptly after Holder exercises or converts this Warrant and, if applicable, the Company receives payment of the aggregate Warrant Price, the Company shall
deliver to Holder certificates for the Shares acquired and, if this Warrant has not been fully exercised or converted and has not expired, a new Warrant representing the Shares not so acquired. 

1.5 Replacement of Warrants. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction
or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of mutilation, on surrender and cancellation of this
Warrant, the Company shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor. 
 1.6 Treatment
of Warrant Upon Acquisition of Company. 
 1.6.1 “Acquisition”. For the purpose of this Warrant,
“Acquisition” means any sale, exclusive license, or other disposition of all or substantially all of the assets of the Company, or any reorganization, consolidation, merger or sale of outstanding capital stock of the Company where the
holders of the Company’s outstanding voting securities before the transaction beneficially own less than a majority of the outstanding voting securities of the surviving entity or, if applicable, its parent entity, after the transaction.

 1.6.2 Treatment of Warrant at Acquisition. 

A) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is not a True Asset Sale (as defined below) in
which the sole consideration is cash, either (a) Holder shall exercise its conversion or purchase right under this Warrant and such exercise will be deemed effective immediately prior to and contingent upon the consummation of such Acquisition
or (b) if Holder elects not to exercise the Warrant, this Warrant will expire upon the consummation of such Acquisition. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such
reasonable information as the Holder may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition.

 B) Upon the written request of the Company, Holder agrees that, in the event of an Acquisition that is an “arms length” sale
of all or substantially all of the Company’s assets (and only its assets) to a third party that is not an Affiliate (as defined below) of the Company (a “True Asset Sale”), either (a) Holder shall exercise its conversion or
purchase right under this Warrant and such exercise will be deemed effective immediately prior to the consummation of such Acquisition or (b) if Holder elects not to exercise the Warrant, this Warrant will continue until the Expiration Date if
the Company continues as a going concern following the closing of any such True Asset Sale. The Company shall provide the Holder with written notice of its request relating to the foregoing (together with such reasonable information as the Holder
may request in connection with such contemplated Acquisition giving rise to such notice), which is to be delivered to Holder not less than ten (10) days prior to the closing of the proposed Acquisition. 

  
 2 

 C) Upon the closing of any Acquisition other than those particularly described in subsections
(A) and (B) above, the successor entity shall assume the obligations of this Warrant, and this Warrant shall be exercisable for the same securities, cash, and property as would be payable for the Shares issuable upon exercise of the
unexercised portion of this Warrant as if such Shares were outstanding on the record date for the Acquisition and subsequent closing. The Warrant Price and/or number of Shares shall be adjusted accordingly. 

D) Notwithstanding the foregoing provisions of this Section 1.6.2., in the event that the acquiror in an Acquisition does not agree to assume
this Warrant at and as of the closing thereof, this Warrant, to the extent not exercised or converted on or prior to such closing, shall terminate and be of no further force or effect as of immediately following such closing if all of the following
conditions are met: (i) the acquiror is subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended, (ii) the class of stock or other security of the acquiror that would
be received by Holder in connection with such Acquisition were Holder to exercise or convert this Warrant on or prior to the closing thereof is listed for trading on a national securities exchange or approved for quotation on an automated
inter-dealer quotation system, and (iii) the value (determined as of the closing of such Acquisition in accordance with the definitive agreements therefor) of the acquiror stock and/or other securities that would be received by Holder in
respect of each Share were Holder to exercise or convert this Warrant on or prior to the closing of such Acquisition is equal to or greater than three (3) times the then-effective Warrant Price. 

As used in this Section 1.6, “Affiliate” shall mean any person or entity that owns or controls directly or indirectly ten
percent (10%) or more of the stock of Company, any person or entity that controls or is controlled by or is under common control with such persons or entities, and each of such person’s or entity’s officers, directors, joint venturers
or partners, as applicable. 
 ARTICLE 2. ADJUSTMENTS TO THE SHARES. 

2.1 Stock Dividends, Splits, Etc. If the Company declares or pays a dividend on the outstanding shares of the Class payable
in common stock or other securities, then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without cost to Holder, the total number and kind of securities to which Holder would have been entitled had Holder owned the
Shares of record as of the date the dividend occurred. If the Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be
proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be
proportionately increased and the number of Shares shall be proportionately decreased. 
 2.2 Reclassification,
Exchange, Combinations or Substitution. Upon any reclassification, exchange, substitution, or other event that results in a change of the number and/or class of the securities issuable upon exercise or conversion of this Warrant, Holder shall be
entitled to receive, upon exercise or conversion of this Warrant, the number and kind of securities and property that Holder would have received for the Shares if this Warrant had been exercised immediately before such reclassification, exchange,
substitution, or other event, and the Warrant Price shall be adjusted proportionately. The Company or its successor shall 

  
 3 

 
promptly issue to Holder an amendment to this Warrant setting forth the number and kind of such new securities or other property issuable upon exercise or conversion of this Warrant as a result
of such reclassification, exchange, substitution or other event that results in a change of the number and/or class of securities issuable upon exercise or conversion of this Warrant. The amendment to this Warrant shall provide for adjustments which
shall be as nearly equivalent as may be practicable to the adjustments provided for in this Article 2 including, without limitation, adjustments to the Warrant Price and to the number of securities or property issuable upon exercise of the new
Warrant. The provisions of this Article 2.2 shall similarly apply to successive reclassifications, exchanges, substitutions, or other events. 
 2.3 Intentionally Omitted. 
 2.4 No Impairment. The Company shall not,
by amendment of its Certificate of Incorporation or through a reorganization, transfer of assets, consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of
any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good faith assist in carrying out of all the provisions of this Article 2 and in taking all such action as may be necessary or appropriate to
protect Holder’s rights under this Article against impairment; provided, however, that notwithstanding the foregoing, nothing in this Section 2.4 shall restrict or impair the Company’s right to effect changes to the rights,
preferences, and privileges associated with the Shares with the requisite consent of the stockholders as may be required to amend the Certificate of Incorporation from time to time so long as such amendment affects the rights, preferences, and
privileges granted to Holder associated with the Shares in the same manner as the other holders of outstanding shares of the Class. 
 2.5 Fractional Shares. No fractional Shares shall be issuable upon exercise or conversion of the Warrant and the number of Shares to be issued shall be rounded down to the nearest whole Share. If a
fractional share interest arises upon any exercise or conversion of the Warrant, the Company shall eliminate such fractional share interest by paying Holder the amount computed by multiplying the fractional interest by the fair market value of a
full Share. 
 2.6 Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of
Shares, the Company shall promptly notify Holder in writing, and, at the Company’s expense, promptly compute such adjustment, and furnish Holder with a certificate of its Chief Financial Officer setting forth such adjustment and the facts upon
which such adjustment is based. The Company shall, upon written request, furnish Holder a certificate setting forth the Warrant Price, Class and number of Shares in effect upon the date thereof and the series of adjustments leading to such Warrant
Price, Class and number of Shares. 
 ARTICLE 3. REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

3.1 Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

 (a) All Shares which may be issued upon the exercise of the purchase right represented by this Warrant shall, upon
issuance, be duly authorized, validly issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws. 

  
 4 

 3.2 Notice of Certain Events. If the Company proposes at any time (a) to
declare any dividend or distribution upon the outstanding shares of the same class and series as the Shares, whether in cash, property, stock, or other securities and whether or not a regular cash dividend; (b) to offer for subscription or sale
pro rata to the holders of the outstanding shares of the same class and series as the Shares any additional shares of any class or series of the Company’s stock; (c) to effect any reclassification, reorganization or recapitalization of the
outstanding shares of the Class; or (d) to effect an Acquisition or to liquidate, dissolve or wind up, then, in connection with each such event, the Company shall give Holder notice thereof at the same time and in the same manner as the Company
notifies the holders of the outstanding shares of the Class thereof. Company will also provide information requested by Holder reasonably necessary to enable the Holder to comply with the Holder’s accounting or reporting requirements, subject
to Holder being bound by customary confidentiality obligations. 
 3.3 No Shareholder Rights. Except as provided in
this Warrant, Holder will not have any rights as a shareholder of the Company until the exercise of this Warrant. 
 ARTICLE 4. REPRESENTATIONS,
WARRANTIES OF THE HOLDER. 
 The Holder represents and warrants to the Company as follows: 

4.1 Purchase for Own Account. This Warrant and the securities to be acquired upon exercise of this Warrant by Holder will be
acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of
acquiring this Warrant or the Shares. 
 4.2 Disclosure of Information. Holder has received or has had full access
to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without
unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3 Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves
substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying securities and has
such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business relationship with
the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4 Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated
under the Act. 
 4.5 The Act. Holder understands that this Warrant and the Shares issuable upon exercise or
conversion hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona 

  
 5 

 
fide nature of the Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise or conversion hereof must be held indefinitely
unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and qualification are otherwise available. 
 ARTICLE 5. MISCELLANEOUS. 
 5.1 Term: This Warrant is exercisable in
whole or in part at any time and from time to time on or before the Expiration Date. 
 5.2 Legends. This Warrant
and the Shares (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 

THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE
SECURITIES LAWS OF ANY STATE AND, EXCEPT FOR AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 OF THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE COMPANY TO SILICON VALLEY BANK DATED AS OF DECEMBER 19, 2011 MAY NOT BE OFFERED, SOLD OR OTHERWISE
TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER OF THESE SECURITIES, SUCH OFFER, SALE OR
TRANSFER, PLEDGE OR HYPOTHECATION IS EXEMPT FROM REGISTRATION. 
 5.3 Compliance with Securities Laws on Transfer.
This Warrant and the Shares issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part without compliance with applicable
federal and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the
Company). The Company shall not require Silicon Valley Bank (“Bank”) to provide an opinion of counsel if the transfer is to Bank’s parent company, SVB Financial Group (formerly Silicon Valley Bancshares), or any other affiliate of
Bank. Additionally, the Company shall also not require an opinion of counsel if there is no material question as to the availability of current information as referenced in Rule 144(c), Holder represents that it has complied with Rule 144(d) and
(e) in reasonable detail, the selling broker represents that it has complied with Rule 144(f), and the Company is provided with a copy of Holder’s notice of proposed sale. 

5.4 Transfer Procedure. After receipt by Holder of the executed Warrant, Bank will transfer all of this Warrant to
Holder’s parent company, SVB Financial Group, by execution of an Assignment substantially in the form of Appendix 2. Subject to the provisions of Article 5.3 and upon providing Company with written notice, SVB Financial Group and any subsequent
Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon conversion of the Shares, if 

  
 6 

 
any) to any transferee, provided, however, in connection with any such transfer, SVB Financial Group or any subsequent Holder will give the Company notice of the portion of the Warrant being
transferred with the name, address and taxpayer identification number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable). The Company may refuse to transfer this
Warrant or the Shares to any person who directly competes with the Company (as determined by Holder), unless, in either case, the stock of the Company is publicly traded. Any transferee shall take this Warrant subject to all provisions and
restrictions contained herein. 
 5.5 Notices. All notices and other communications from the Company to the Holder,
or vice versa, shall be deemed delivered and effective when given personally or mailed by first-class registered or certified mail, postage prepaid, at such address, as may have been furnished to the Company or the Holder, as the case may (or on the
first business day after transmission by facsimile) be, in writing by the Company or such Holder from time to time. Effective upon receipt of the fully executed Warrant and the initial transfer described in Article 5.4 above, all notices to the
Holder shall be addressed as follows until the Company receives notice of a change of address in connection with a transfer or otherwise: 
 SVB Financial Group 
 Attn: Treasury Department 

3003 Tasman Drive, HA 200 

Santa Clara, CA 95054 

Telephone: 408-654-7400 

Facsimile: 408-496-2405 
 Notice to the Company shall be addressed as follows until the Holder receives notice of a change in address: 
 Somaxon Pharmaceuticals, Inc. 
 Attn: Tran Nguyen, Chief Financial
Officer 
 10935 Vista Sorrento Parkway, Suite 250 

San Diego, CA 92130 

Telephone: (858) 876-6510 

Facsimile: (858) 509-1761 

with copies to: 
 Somaxon Pharmaceuticals, Inc. 
 Attn: Matthew W. Onaitis, General
Counsel 
 10935 Vista Sorrento Parkway, Suite 250 

San Diego, California 92130 

Fax: (858) 509-1761 

Latham & Watkins LLP 

Attn: Cheston J. Larson, Esq. 

12636 High Bluff Drive, Suite 400 

San Diego, California 92130 

Fax: (858) 523-5450 

  
 7 

 5.6 Waiver. This Warrant and any term hereof may be changed, waived, discharged
or terminated only by an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 
 5.7 Attorney’s Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the party prevailing in such dispute shall be entitled to collect from the other
party all costs incurred in such dispute, including reasonable attorneys’ fees. 
 5.8 Automatic Conversion upon
Expiration. In the event that, upon the Expiration Date, the fair market value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect
on such date, then this Warrant shall automatically be deemed on and as of such date to be converted pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised or converted,
and the Company shall promptly deliver a certificate representing the Shares (or such other securities) issued upon such conversion to Holder. 
 5.9 Counterparts. This Warrant may be executed in counterparts, all of which together shall constitute one and the same agreement. 
 [Remainder of page left blank intentionally] 

  
 8 

 5.10 Governing Law. This Warrant shall be governed by and construed in
accordance with the laws of the State of California, without giving effect to its principles regarding conflicts of law. 
  

			
	“COMPANY”
	
	SOMAXON PHARMACEUTICALS, INC.
		
	By:	 	/s/ MATTHEW W. ONAITIS
		
	Name: 	 	MATTHEW W. ONAITIS
		 	(Print)
	Title:	 	 SVP AND GENERAL COUNSEL

	
	“HOLDER”
	
	SILICON VALLEY BANK
		
	By:	 	/s/ KEVIN WALLACE
		
	Name: 	 	KEVIN WALLACE
		 	(Print)
	Title:	 	 RELATIONSHIP MANAGER

 Silicon Valley Bank 
 Warrant 

 APPENDIX 1 
 NOTICE OF EXERCISE 
 1. Holder elects to purchase
            shares of the Common Stock of SOMAXON PHARMACEUTICALS, INC. pursuant to the terms of the attached Warrant, and tenders payment of the purchase price of the shares in full.

 [or] 
 1. Holder elects to convert the attached Warrant into Shares/cash [strike one] in the manner specified in the Warrant. This conversion is exercised for
            of the Shares covered by the Warrant. 
 [Strike
paragraph that does not apply.] 
 2. Please issue a certificate or certificates representing the shares in the name
specified below: 
  

					
		 	 	 	
		 	    Holders Name	 	
			
		 	 	 	
			
		 	 	 	
		 	     (Address)
	 	

 3. By its execution below and for the benefit of the Company, Holder hereby restates each of the
representations and warranties in Article 4 of the Warrant as the date hereof. 
  

			
	
	HOLDER:
	
	 
		
	By:	 	 
		
	Name: 	 	 
		
	Title:	 	 
		
	(Date): 	 	 

 APPENDIX 2 
 ASSIGNMENT 
 For value received, Silicon Valley Bank hereby sells, assigns and transfers unto

  

					
		 	 Name:
	    	SVB Financial Group
		 	 Address:
	    	3003 Tasman Drive (HA-200)
		 		    	Santa Clara, CA 95054
		 	 Tax ID: 91-1962278
	    	

 that certain Warrant to Purchase Stock issued by SOMAXON PHARMACEUTICALS, INC. (the “Company”), on
December 19, 2011 (the “Warrant”) together with all rights, title and interest therein. 
  

			
	SILICON VALLEY BANK
		
	 By:
	 	 
		
	 Name: 
	 	 
		
	 Title:
	 	 

  

			
	Date: 	 	 

 By its execution below, and for the benefit of the Company, SVB Financial Group makes each of the representations
and warranties set forth in Article 4 of the Warrant and agrees to all other provisions of the Warrant as of the date hereof. 
  

			
	SVB FINANCIAL GROUP
		
	 By:
	 	 
		
	 Name: 
	 	 
		
	 Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}]]